Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis

被引：0
|
作者：
Spelman, T. [1 ]
Acosta, C. [2 ]
Hyde, R. [2 ]
Campbell, N. [3 ]
Havrdova, E. [4 ,5 ]
Horakova, D. [4 ,5 ]
Trojano, M. [6 ]
De Luca, G. [7 ]
Lugaresi, A. [8 ,9 ]
Izquierdo, G. [10 ]
Grammond, P. [11 ]
Duquette, P. [12 ,13 ,14 ]
Alroughani, R. [15 ]
Pucci, E. [16 ]
Granella, F. [17 ]
Lechner-Scott, J. [18 ,19 ]
Sola, P. [20 ]
Ferraro, D. [20 ]
Grand-Maison, F. [21 ]
Terzi, M. [22 ]
Rozsa, C. [23 ]
Boz, C. [24 ]
Hupperts, R. [25 ]
Van der Walt, A. [26 ]
Van Pesch, V. [27 ]
Oreja-Guevara, C. [28 ,29 ]
Jokubaitis, V. [1 ]
Kalincik, T. [30 ,31 ]
Butzkueven, H. [32 ,33 ,34 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] Biogen Int, Baar, Switzerland
[3] Biogen, Cambridge, MA USA
[4] Charles Univ Prague, Prague, Czech Republic
[5] Gen Univ Hosp Prague, Prague, Czech Republic
[6] Univ Bari, Bari, Italy
[7] SS Annunziata Hosp, Chieti, Italy
[8] Univ Bologna, IRCCS Ist Sci Neurol Bologna, Bologna, Italy
[9] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy
[10] Hosp Univ Virgen Macarena, Seville, Spain
[11] CISSS Chaudicre Appalache, Levis, PQ, Canada
[12] Hop Notre Dame De Bon Secours, Montreal, PQ, Canada
[13] CHUM, Montreal, PQ, Canada
[14] Univ Montreal, Montreal, PQ, Canada
[15] Amiri Hosp, Sharq, Kuwait
[16] Azienda Sanit Unica Reg Marchef AV3, UOC Neurol, Macerata, Italy
[17] Univ Parma, Parma, Italy
[18] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia
[19] John Hunter Hosp, Hunter New England Health, Dept Neurol, Newcastle, NSW, Australia
[20] Azienda Osped Univ, Modena, Italy
[21] Neuro Rive Sud, Greenfield Pk, PQ, Canada
[22] 19 Mayis Univ, Samsun, Turkey
[23] Jahn Ferenc Teaching Hosp, Budapest, Hungary
[24] KTU Med Fac Farabi Hosp, Trabzon, Turkey
[25] Zuyderland Ziekenhuis, Sittard, Netherlands
[26] Monash Univ, Cent Clin Sch, Dept Neurosci, Alfred Hlth,Clin Neurosci, Melbourne, Vic, Australia
[27] Clin Univ St Luc, Brussels, Belgium
[28] Hosp Clin San Carlos, IdISSC, Madrid, Spain
[29] Univ Complutense, Hosp Univ La Paz, Madrid, Spain
[30] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia
[31] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia
[32] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[33] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia
[34] Monash Univ, Box Hill Hosp, Dept Neurol, Melbourne, Vic, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0859
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [1] Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
    Spelman, T.
    Herring, W. L.
    Acosta, C.
    Hyde, R.
    Jokubaitis, V. G.
    Pucci, E.
    Lugaresi, A.
    Laureys, G.
    Havrdova, E. K.
    Horakova, D.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Alroughani, R.
    Kalincik, T.
    Duquette, P.
    Girard, M.
    Petersen, T.
    Patti, F.
    Csepany, T.
    Granella, F.
    Grand'Maison, F.
    Ferraro, D.
    Karabudak, R.
    Jose Sa, M.
    Trojano, M.
    van Pesch, V.
    Van Wijmeersch, B.
    Cartechini, E.
    Mccombe, P.
    Gerlach, O.
    Spitaleri, D.
    Rozsa, C.
    Hodgkinson, S.
    Bergamaschi, R.
    Gouider, R.
    Soysal, A.
    Prevost, J.
    Garber, J.
    de Gans, K.
    Ampapa, R.
    Simo, M.
    Sanchez-Menoyo, J. L.
    Iuliano, G.
    Sas, A.
    van der Walt, A.
    John, N.
    Gray, O.
    Hughes, S.
    De Luca, G.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 109 - 125
  • [2] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [3] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [4] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
    Baroncini, Damiano
    Ghezzi, Angelo
    Annovazzi, Pietro O.
    Colombo, Bruno
    Martinelli, Vittorio
    Minonzio, Giorgio
    Moiola, Lucia
    Rodegher, Mariaemma
    Zaffaroni, Mauro
    Comi, Giancarlo
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
  • [5] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [6] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196
  • [7] A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK
    Montgomery, Stephen M.
    Maruszczak, Maciej J.
    Slater, David
    Kusel, Jeanette
    Nicholas, Richard
    Adlard, Nicholas
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 474 - 482
  • [8] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Hanni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Ozgur
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
  • [9] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [10] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
12345